- Home
- WLTH vs TRVI Comparison
WLTH vs TRVI Comparison
Compare WLTH & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$12.28
Company Overview
Basic Information| Metric | WLTH | TRVI |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.5B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | WLTH | TRVI |
|---|---|---|
| Price | $8.47 | $12.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | $17.13 | ★ $20.38 |
| AVG Volume (30 Days) | 1.1M | ★ 1.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.25 | N/A |
| Revenue Next Year | $14.99 | N/A |
| P/E Ratio | $10.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.20 | $4.24 |
| 52 Week High | $14.12 | $14.39 |
Technical Indicators
Market Signals| Indicator | WLTH | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 45.75 | 63.47 |
| Support Level | $7.63 | $11.91 |
| Resistance Level | $9.25 | $14.39 |
| Average True Range (ATR) | 0.64 | 0.65 |
| MACD | 0.15 | 0.22 |
| Stochastic Oscillator | 55.26 | 85.25 |
Price Performance
Historical Comparison WLTH
TRVI
About WLTH Wealthfront Corporation Common Stock
Wealthfront Corp is a technology company that built a financial solutions platform for digital natives. Its platform is designed to address the needs of the wealth builders within these generations.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.